Apoptotic pathway components – secondary downstream effects

Apoptotic pathway components – secondary downstream effects refers to the sequence of molecular events that occur after the initial commitment to programmed cell death (Source: StatPearls, 2023). This phase is characterized by the activation of executioner caspases, such as Caspase-3 and Caspase-7, which orchestrate the systematic dismantling of the cell by cleaving structural and functional proteins (Source: PubMed, PMID: 11257105). These downstream effects are the ultimate goal of many cytotoxic and targeted oncology therapies, including BCL-2 inhibitors like Venetoclax and traditional chemotherapeutic agents (Source: FDA, 2016). Because this term describes a broad biological process involving multiple enzymes and structural proteins, it is classified as a pathway effect rather than a single therapeutic target. Understanding these downstream consequences is vital for assessing drug efficacy and monitoring cellular response to treatment in diseases like cancer and neurodegeneration. The process ensures that cell death occurs in a controlled manner, often avoiding the massive inflammatory response associated with necrosis (Source: NIH, 2022).

Other names

Secondary apoptotic signalingDownstream apoptotic cascadeExecution phase of apoptosisApoptotic effector mechanisms

Induction of the executioner phase of programmed cell death, typically involving the activation of executioner caspases (caspase-3, -6, and -7) leading to proteolysis, chromatin condensation, and DNA fragmentation (Source: StatPearls, 2023).